Previous Article | Next Article 
Infection and Immunity, September 2007, p. 4423-4431, Vol. 75, No. 9
0019-9567/07/$08.00+0 doi:10.1128/IAI.00528-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Serogroup-Related Escape of Yersinia enterocolitica YopE from Degradation by the Ubiquitin-Proteasome Pathway
Moritz Hentschke,1
Konrad Trülzsch,2
Jürgen Heesemann,2
Martin Aepfelbacher,1 and
Klaus Ruckdeschel1*
Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany,1
Max von Pettenkofer Institute for Hygiene and Medical Microbiology, Pettenkoferstrasse 9a, 80336 Munich, Germany2
Received 13 April 2007/
Returned for modification 22 May 2007/
Accepted 18 June 2007

ABSTRACT
Pathogenic
Yersinia spp. employ a type III protein secretion
system that translocates several
Yersinia outer proteins (Yops)
into the host cell to modify the host immune response. One strategy
of the infected host cell to resist the bacterial attack is
degradation and inactivation of injected bacterial virulence
proteins through the ubiquitin-proteasome pathway. The cytotoxin
YopE is a known target protein of this major proteolytic system
in eukaryotic cells. Here, we investigated the sensitivity of
YopE belonging to different enteropathogenic
Yersinia enterocolitica serogroups to ubiquitination and proteasomal degradation. Analysis
of the YopE protein levels in proteasome inhibitor-treated versus
untreated cells revealed that YopE from the highly pathogenic
Y. enterocolitica serotype O8 was subjected to proteasomal destabilization,
whereas the YopE isotypes from serogroups O3 and O9 evaded degradation.
Accumulation of YopE from serotypes O3 and O9 was accompanied
by an enhanced cytotoxic effect. Using
Yersinia strains that
specifically produced YopE from either
Y. enterocolitica O8
or O9, we found that only the YopE protein from serogroup O8
was modified by polyubiquitination, although both YopE isotypes
were highly homologous. We determined two unique N-terminal
lysines (K62 and K75) in serogroup O8 YopE, not present in serogroup
O9 YopE, that served as polyubiquitin acceptor sites. Insertion
of either lysine in serotype O9 YopE enabled its ubiquitination
and destabilization. These results define a serotype-dependent
difference in the stability and activity of the
Yersinia effector
protein YopE that could influence
Y. enterocolitica pathogenesis.

INTRODUCTION
Pathogenic microorganisms have evolved complex tactics to manipulate
the immune response of the host. An archetypical pathogen for
studying the interaction between bacteria and the host cell
is the gram-negative bacterium
Yersinia. Three
Yersinia spp.
can cause diseases in humans and rodents. These are
Yersinia pestis, the causative agent of bubonic plague, and
Yersinia enterocolitica and
Yersinia pseudotuberculosis, which mediate
gastrointestinal syndromes, lymphadenitis, and septicemia (
9).
Although the
Yersinia spp. take different routes of infection,
they share the characteristic that they survive and multiply
extracellularly in the host lymphoid tissue. This ability depends
on the presence of a common, plasmid-encoded type III protein
secretion system that acts as a
Yersinia core virulence determinant
(
9,
18). The type III protein secretion system is activated
upon host cell contact. It mediates the polarized translocation
of
Yersinia effector proteins (
Yersinia outer proteins, or Yops)
inside eukaryotic cells, where the Yops interfere with critical
signaling processes of the host immune response. The Yops neutralize
a sequence of programmed effector functions of host immunity.
YopE, YopT, YopH, and YopO/YpkA inhibit rearrangements of the
actin cytoskeleton that otherwise mediate internalization of
the bacteria by the infected cell (
6,
9,
18). This helps
Yersinia to prevent its uptake and killing by phagocytes. Interestingly,
YopE, YopT, and YopO/YpkA all act on members of the Rho-GTPase
family (
2,
6). The Rho-GTPases regulate the dynamics of the
actin cytoskeleton and a multitude of other cellular functions.
YopE is a GTPase-activating protein which inactivates Rho-GTPases
by increasing their intrinsic GTPase activity (
5,
45). This
switches the GTPases into an inactive state. YopT is a cysteine
protease that represses Rho-GTPase members by cleaving off their
C-terminal isoprenoid moieties (
35). The serine/threonine kinase
YopO/YpkA possesses a Rac1 binding domain that mimics Rho guanidine
nucleotide dissociation inhibitors. YopO/YpkA consequently inhibits
the nucleotide exchange in Rac1 and RhoA which locks these GTPases
in an inactive state (
31). YopH dismantles peripheral focal
adhesion complexes by dephosphorylating host cell proteins,
such as p130Cas and the focal adhesion kinase (
4,
28). Furthermore,
Yersinia represses the proinflammatory response of infected
cells and triggers apoptosis in macrophages. These effects are
mediated by YopP/YopJ, which acetylates members of the mitogen-activated
protein kinase kinase superfamily and the NF-

B-activating I

B
kinase-ß. These events deactivate the mitogen-activated
protein kinase and NF-

B signaling pathways and prevent the production
of protective cytokines, such as tumor necrosis factor alpha
and interleukin-8 (
25-
27).
While these immunomodulatory activities of Yops have been intensively studied, little is known about the reaction of the host cell to Yop infection. Our previous studies have shown that the infected cell has developed mechanisms to counteract the Yop effects. It was revealed that YopE is degraded and inactivated through the ubiquitin-proteasome pathway after it has been translocated inside the host cell (32). The proteasome is a self-compartmentalizing protease complex that executes the controlled breakdown of intracellular proteins. It regulates the half-life of the vast majority of the eukaryotic proteins and thereby contributes to maintain cellular homeostasis (12, 29). The proteins that are destined for proteasomal destruction are marked with lysine-48-linked polyubiquitin chains to allow recognition and processing by the proteasome complex in order to generate oligopeptides and recyclable ubiquitin (29, 39). This protein-editing function mediates the processing of intracellular antigens for presentation by major histocompatibility complex class I (21). Additionally, the ubiquitin-proteasome system apparently plays a direct role in the innate immune response against bacterial infection. Our data have demonstrated that the degradation of YopE by the proteasome contributes to reverse the antiphagocytic effect of Yersinia (32). This indicates an immediate function of the proteasome to fight bacterial infection. In line with this conclusion, several other bacterial effector proteins have been demonstrated to be subjected to proteasomal degradation. Accordingly, SopE and SopA from Salmonella enterica and ExoT from Pseudomonas aeruginosa are target molecules of the ubiquitin-proteasome pathway (3, 22, 49). The inactivation of ExoT participates to limit P. aeruginosa-mediated disease (3). This suggests that the modification with polyubiquitin and the subsequent destruction by the proteasome could be a basic strategy of the host cell to restrict the activities of a subset of bacterial proteins translocated via type III protein secretion.
In this study, we analyzed several pathogenic Y. enterocolitica serotypes for the susceptibilities of their YopE protein species to degradation by the ubiquitin-proteasome pathway. We report that YopE of Y. enterocolitica serogroups O3 and O9 evades polyubiquitination and proteasomal destabilization. In contrast, YopE from serotype O8 is effectively ubiquitinated and inactivated. The susceptibility of the YopE O8 isotype to polyubiquitination and degradation is determined by two critical lysine residues in the YopE N terminus (K62 and K75). These lysines are absent in the YopE protein species from serogroups O3 and O9. Introduction of these lysine residues in YopE from serogroup O9 induces YopE ubiquitination and destabilization, whereas replacement of the lysines in YopE from serogroup O8 by arginine and glutamine of YopE O9 stabilizes the YopE protein levels and its cytotoxic effect. Thus, the amino acids at positions 62 and 75 critically control the stability and activity of the Yersinia effector protein YopE. The susceptibility of YopE to polyubiquitination could be relevant for differential function and virulence of Y. enterocolitica serotypes.

MATERIALS AND METHODS
Yersinia strains, cell lines, and infection conditions.
The
Y. enterocolitica strains used in this study are listed
in Table
1. Three different
Y. enterocolitica wild-type strains
(WA-314, E40, and 108-P) and a virulence plasmid-cured derivative
of strain WA-314, termed WA-C, were investigated. The
Y. enterocolitica serotype O9 strain E40 (
38) was kindly provided by G. R. Cornelis
(Biozentrum der Universität Basel, Basel, Switzerland).
Furthermore, we utilized a number of
Yersinia strains that produced
diverse isotypes of YopE as the sole effector Yop. These strains
harbor one plasmid encoding the Yop secretion and translocation
machinery (pTTSS, where TTSS is type III secretion system) and
a second plasmid encoding the YopE module (pYopE-SycE) either
from strain WA-314 (WA-TTSS/YopE
O8, where YopE
O8 is YopE from
the
Y. enterocolitica serogroup O8) or E40 (WA-TTSS/YopE
O9),
respectively (
32,
41). The resulting strains produce only YopE
but no other effector Yop. For the mutagenesis of YopE in these
strains, point mutations were inserted into the wild-type
yopE genes by using a QuikChange site-directed mutagenesis kit according
to the manufacturer's instructions (Stratagene, La Jolla, CA).
For infection, overnight cultures grown at 27°C were diluted
1:20 in fresh Luria-Bertani broth and grown for another 2 h
at 37°C. Shift of the growth temperature to 37°C initializes
activation of the
Yersinia type III secretion machinery for
efficient translocation of Yops into the host cell upon cellular
contact (
32). To equalize and synchronize infection, bacteria
were seeded on the cells by centrifugation at 400
x g for 5
min at a ratio of 50 to 100 bacteria per cell. For incubation
times longer than 90 min, bacteria were killed by the addition
of gentamicin (100 µg/ml) after 90 min. The human embryonic
kidney 293 (HEK293) cell line was cultured in Dulbecco's modified
Eagle's medium containing 10% heat-inactivated fetal calf serum
(Invitrogen, Karlsruhe, Germany). Where indicated, the cells
were treated with a 5 µM concentration of the proteasome
inhibitor MG-132 (Z-Leu-Leu-Leu-CHO; Biomol, Plymouth Meeting,
PA) 30 min prior to infection, unless stated otherwise. The
application of the proteasome inhibitor did not trigger apoptosis
or cytotoxically alter the viability of the cells by another
mechanism within the investigated time frames (
32).
Western immunoblotting, immunoprecipitation, and cell transfection.
For assessment of the cellular YopE levels, infected cells were solubilized, at the time points indicated in the figure legends, with a buffer containing 10 mM HEPES, pH 7.8, 10 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 0.1% NP-40, 1 mM dithiothreitol, and phosphatase and protease inhibitors (Roche, Mannheim, Germany). The lysates were cleared by centrifugation, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane, and probed with polyclonal antibodies directed against YopE (32). Immunoreactive bands were visualized using appropriate secondary antibodies and enhanced chemiluminescence detection reagents (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). To overexpress ubiquitin for the YopE immunoprecipitation experiments, HEK293 cells were seeded in six-well cell culture plates and transfected with a human cDNA construct encoding an octameric tandem fusion of hemagglutinin-ubiquitin (40) or empty control vector. Transfections were conducted by the calcium-phosphate transfection method as described previously (13). The ubiquitin expression vector was kindly provided by M. Treier (European Molecular Biology Laboratory, Heidelberg, Germany). Eighteen hours after transfection, the cells were infected with Yersinia strains and processed for immunoprecipitation similarly to nontransfected cells. Accordingly, the cells were lysed 90 min after onset of infection with a lysis buffer containing 50 mM Tris, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µM MG-132, a cocktail of protease inhibitors (Roche), and a 10 µM concentration of the deubiquitinase inhibitor N-ethylmaleimide (22, 32). The lysates were preabsorbed to protein A/G-agarose (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at 4°C and then incubated with rabbit polyclonal antibodies directed against YopE or flagellin as a negative control serum for 16 h at 4°C to precipitate YopE from the infected cells (32, 46). The immune complexes were collected with protein A/G-agarose (Santa Cruz Biotechnology, Santa Cruz, CA), washed five times with lysis buffer, and subjected to Western immunoblotting as described above. Ubiquitin-YopE conjugates were detected by immunoblotting with the monoclonal mouse anti-ubiquitin antibody FK2 (Biomol International, Plymouth Meeting). When required, the membranes were stripped in 62.5 mM Tris, pH 6.7, 0.1 mM 2-mercaptoethanol, and 2% sodium dodecyl sulfate for 30 min at 50°C and reused for a second immunoblotting procedure. This stripping method was also applied to recycle the membranes for successive labeling with anti-YopE antibodies and for controlling equal protein loading of the gels by detecting ß-tubulin with mouse monoclonal antibody (D-10; Santa Cruz Biotechnology, Santa Cruz, CA) in the cellular lysates. The shown data are from one experiment and are representative for at least three performed.

RESULTS
YopE from Y. enterocolitica serogroups O9 and O3 evades destabilization by the host cell proteasome.
Our previous studies demonstrated that YopE of
Y. enterocolitica serogroup O8 is subjected to proteasomal degradation after it
is translocated inside the host cell. The destabilization of
YopE by the proteasome helps to restrict and to counteract the
immunomodulatory activities of the Yop in the infected cell
(
32). YopE is one of the major Yops that mediate reorganization
of the actin cytoskeleton and thereby induce a typical, contracted
or rounded morphology of the infected cells. We found that the
cytotoxic effect of YopE is enhanced when the degradation of
YopE by the proteasome is prevented by the application of proteasome-inhibitory
compounds (
32). Here, we analyzed the influence of the proteasome
inhibitor MG-132 on the appearance of HEK293 cells that were
infected with different pathogenic serotypes of
Y. enterocolitica.
The peptide MG-132 serves as substrate analogue of the proteasome
and thereby blocks its protease activity (
23). Figure
1 A shows
that the serotype O8 strain WA-314 induced a characteristic,
contracted cell morphology. This effect was enhanced by MG-132
treatment, with the cells displaying a pronounced rounding phenotype
compared to untreated cells. Replacement of MG-132 by the proteasome
inhibitor epoxomicin (
24) provided comparable results (
32; also
data not shown). The virulence plasmid-cured strain WA-C was
unable to alter the morphology of the infected cells, whether
they were treated with MG-132 or not (Fig.
1A). This confirms
the idea that cell rounding is mediated by some of the effector
Yops, most likely involving YopE (
2,
6,
9,
32). Surprisingly,
rounding of cells infected with the
Y. enterocolitica serotype
O9 strain E40 was not intensified by MG-132 (Fig.
1A). E40-infected
cells displayed a severely rounded phenotype similar to that
of MG-132-treated cells infected with the O8 strain under the
same conditions. In the same manner, cytotoxicity conferred
by the serogroup O3 strain 108-P was not pronounced upon proteasome
inhibition. This suggests that the cytotoxic effects conferred
by strains E40 and 108-P, which most likely are brought about
by YopE activity, are not influenced by the host cell proteasome.
We subsequently investigated whether the different cell-rounding
activities of the
Y. enterocolitica serotypes could be related
to differences in the regulation of YopE stability. HEK293 cells
were infected with the diverse
Yersinia strains in the absence
or presence of the proteasome inhibitor, and the protein levels
of translocated YopE were examined in cellular lysates by immunoblotting
with antibodies directed against YopE. Figure
1B shows that
addition of the proteasome inhibitor markedly enhanced the protein
levels of YopE from
Y. enterocolitica serogroup O8. In contrast,
the YopE levels from serogroups O9 and O3, appearing as double
protein bands, were not affected by MG-132 and instead remained
constant. This suggests that the proteasome pathway governs
the stability of YopE
O8, but not from the serogroups O9 and
O3 (YopE
O9 and YopE
O3, respectively). This finding could explain
why the cytotoxic activity of only YopE
O8 increases in proteasome
inhibitor-treated cells. The proteasome apparently degrades
and inactivates YopE
O8 but not YopE
O9 or YopE
O3. YopE
O9 and
YopE
O3, instead, appear to be subjected to another form of modification.
The double protein band detected for YopE
O9 and YopE
O3 (Fig.
1B) could be consistent with intracellular processing of YopE
O9 and YopE
O3. The nature and significance of this modification,
however, are not yet clear.
We next attempted to analyze the relationship between the stabilities of the different YopE isotypes and their primary structures. For that reason, we sequenced the yopE genes of the investigated strains and compared the deduced YopE amino acid sequences (Fig. 2). The sequence of the serogroup O8 strain WA-314 corresponds to the published sequences of YopEO8 from strain A127/90 (accession no. NP_783702), whereas YopE from strain E40 was homologous to YopEO9 from strain W22703 (accession no. NP_052427). Finally, YopE from the serogroup O3 strain 108-P, which behaved like YopEO9 in our experiments (Fig. 1B), was identical to serogroup O9 YopE (data not shown). Figure 2 shows that the amino acid sequences of YopEO8 and YopEO9 are highly homologous (93.6% identity). Single amino acids that differ between the two serogroups are marked in boldface. Interestingly, at positions 62 and 75 YopEO9 lacks two lysine residues that are present in YopEO8. Conjugation of lysine residues with ubiquitin moieties is the best-characterized posttranslational modification event that targets cellular proteins to the proteasome for degradation (29, 39). In fact, one of the two lysines (lysine-75) was already identified to be involved in mediating the destabilization of YopEO8 (32). On this basis, we explored the possibility that translocated YopEO9 could escape the modification with polyubiquitin inside the host cell because it lacks the two lysines (Fig. 2). This could prevent its degradation through the proteasome pathway.
To be able to characterize the ubiquitination of YopE
O8 and
YopE
O9 in parallel under otherwise identical conditions, we
constructed two
Yersinia strains that translocate either YopE
O8 or YopE
O9 as the sole effector Yop. These strains harbor two
plasmids (
32,
41), one encoding the structural and regulatory
components of the
Y. enterocolitica type III protein secretion
system and the other encoding YopE either from the serogroup
O8 strain WA-314 (resulting in strain WA-TTSS/ YopEO8) or the
serogroup O9 strain E40 (resulting in WA-TTSS/YopEO9). These
two strains were then used to infect HEK293 cells, and the virulence
plasmid-cured strain WA-C served as a negative control. A
Yersinia strain that expresses the secretion-translocation module without
YopE is not an adequate control because this strain causes necrotic
cell death (
44; also data not shown). This nonspecific effect
is thought to result from the formation of pores in the host
cell membrane by the
Yersinia type III protein secretion apparatus
in the absence of YopE. YopE likely inhibits the pore-forming
activity by reducing F-actin that somehow is required for keeping
the pores open (
44). The cells were treated with the proteasome
inhibitor MG-132 prior to infection, a procedure that causes
the accumulation of proteins which are destined for proteasomal
degradation. The YopE proteins were then immunoprecipitated
from cellular lysates with anti-YopE antibodies and immunoblotted
with anti-ubiquitin antibody to detect ubiquitin-modified YopE
protein species. Figure
3 shows that a number of anti-ubiquitin
antibody-immunoreactive bands specifically precipitated with
YopE
O8. These ubiquitin-modified protein species migrated with
slower electrophoretic mobilities than unmodified YopE
O8 (23
kDa) and were separated from original YopE by increasing distances,
starting from about 8 kDa. These higher molecular weights are
consistent with the modification of YopE
O8 by mono- and polyubiquitination.
In fact, the majority of the ubiquitinated proteins were detected
also by the anti-YopE antibody (Fig.
3, right panel), which
gives evidence that the ubiquitin-modified proteins represent
ubiquitinated YopE
O8 protein species. These YopE-ubiquitin bands
were not found in either the precipitates prepared from WA-C-infected
cells or in control samples using an anti-flagellin antibody.
Furthermore, no substantial ubiquitination was detected in the
immunoprecipitates of YopE
O9. The elevated protein levels in
the YopE
O8 immunoprecipitates compared to those of YopE
O9 probably
result from the accumulation of YopE
O8 upon proteasome inhibition,
which is not observed for YopE
O9 (Fig.
1B). These results indicate
that YopE
O8 is subjected to ubiquitination inside the
Yersinia-infected
host cell, whereas YopE
O9 evades ubiquitination. In agreement
with the role of polyubiquitin moieties in targeting a selected
protein for proteasomal destruction (
12,
29,
39), the failure
of YopE
O9 to be modified by polyubiquitination apparently prevents
its degradation by the host proteasome.
Loss of the lysines-62 and -75 protects YopE against polyubiquitination and proteasomal destabilization.
To specify the impact of lysine-62 and -75 on the ubiquitination
and stability of translocated YopE, we mutated the two lysines
of YopE
O8 either individually or together. They were replaced
by arginine or glutamine, which are located at the respective
amino acid positions in YopE
O9 [resulting in plasmids YopE
O8(K62R),
YopE
O8(K75Q), and YopE
O8(K62R K75Q)]. In the same manner, we
replaced arginine-62 and glutamine-75 in YopE
O9 with lysine
residues [resulting in plasmids YopE
O9(R62K), YopE
O9(Q75K),
and YopE
O9(R62K Q75K)]. These YopE mutant proteins were then
used to replace the wild-type YopE isotypes in strains WA-TTSS/YopE
O8 [resulting in strains WA-TTSS/YopE
O8(K62R), WA-TTSS/YopE
O8(K75Q),
and WA-TTSS/YopE
O8(K62R, K75Q)] and WA-TTSS/YopEO9 [resulting
in strains WA-TTSS/YopE
O9(R62K), WA-TTSS/YopE
O9(Q75K), and WA-TTSS/YopE
O9(R62K
Q75K)], respectively. The cellular effects of the different
strains were compared (Fig.
4). These experiments revealed that
the mutation of only one lysine in YopE
O8, either at position
62 or 75, could not significantly diminish the polyubiquitination
of YopE
O8 [Fig.
4A, strains WA-TTSS/YopE
O8(K62R) and WA-TTSS/YopE
O8(K75Q)].
In contrast, the ubiquitination of YopE
O8 was abolished when
both lysines were mutagenized [Fig.
4A, strain WA-TTSS/YopE
O8(K62R
K75Q)]. The negative controls applying anti-flagellin instead
of anti-YopE antibodies in the immunoprecipitations in Fig.
4 did not show significant ubiquitination patterns (data not
shown). This indicates that lysine-62 as well as lysine-75 can
serve as ubiquitin acceptor sites and that only the loss of
both lysines efficiently prevents the polyubiquitination of
YopE
O8. The importance of these lysine residues in enabling
YopE ubiquitination was confirmed by studies on YopE
O9. Accordingly,
the YopE
O9 double point mutant that harbors both lysines at
positions 62 and 75 was efficiently ubiquitinated [Fig.
4B,
strain WA-TTSS/YopE
O9(R62K Q75K)]. In contrast, the YopE
O9 mutants
with only one of these lysine residues did not exhibit remarkable
polyubiquitination in this set of experiments [Fig.
4B, strains
WA-TTSS/YopE
O9(R62K) and WA-TTSS/YopE
O9(Q75K)]. A faint band
that appeared in the anti-YopE immunoblot could be consistent
with a weak modification of these YopE
O9 mutant proteins by
monoubiquitination (Fig.
4B, right panel). However, when ubiquitin
was overexpressed in the infected HEK293 cells, both single
lysine mutants of YopE
O9 became efficiently mono- and polyubiquitinated
(Fig.
4C). This confirms that either lysine can principally
ensure the ubiquitination of YopE. The effective and proper
ubiquitination of YopE under more restricted conditions with
physiological ubiquitin levels may, however, be influenced by
the secondary structure of YopE
O9 and require the presence of
both lysine residues.
Having characterized the ubiquitination pattern of the different
YopE point mutants, we next studied their intracellular stability
in response to treatment with the proteasome inhibitor (Fig.
5). The results showed that the levels of the YopE protein species
that harbor at least one lysine at either position 62 or 75
[YopE
O8, YopE
O8(K62R), YopE
O8(K75Q), YopE
O9(R62K), YopE
O9(Q75K),
and YopE
O9(R62K Q75K)] increased upon proteasome inhibitor treatment.
This effect correlated with the ability of these YopE proteins
to become polyubiquitinated (Fig.
4). The insertion of alanines
instead of the lysines in YopE
O9 [Fig.
5, compare strains WA-TTSS/YopE
O9(R62A
Q75A) and WA-TTSS/YopE
O9(R62K Q75K)] did not increase the quantity
of YopE upon proteasome inhibition, suggesting that the accumulation
of YopE
O9 in proteasome-inhibited cells is specifically mediated
by lysine insertion. YopE
O9 and YopE
O8(K62R K75Q), which do
not undergo polyubiquitination, were not stabilized by treatment
with the proteasome inhibitor. These results show that lysine-62
and -75 determine the predisposition of YopE to become subjected
to ubiquitination and proteasomal degradation.
Microscopic evaluations of the infected cells further revealed
that lysine-62 and -75 also control the cytotoxic activity of
YopE on the host cell. Only YopE
O9, YopE
O8(K62R K75Q), and YopE
O9(R62A
Q75QA), which resist polyubiquitination because of the absence
of lysine-62 and -75, induced a pronounced rounded phenotype
in both the presence and absence of MG-132 (Fig.
6). In contrast,
the morphological cell alterations induced by the other investigated
YopE protein species, which harbor at least either lysine-62
or -75, were enforced by MG-132 treatment [Fig.
6, YopE
O8 and
YopE
O9(R62K Q75K)] (data not shown). The cellular effects of
these Yops are thus enhanced by MG-132 exposure according to
their protein levels. Together, these data indicate that loss
of the two lysine residues 62 and 75 provides YopE with the
ability to escape polyubiquitination. This increases its intracellular
stability and concomitantly enhances its cytotoxic potential
on the host cell. It may be concluded from these observations
that the protection of YopE
O9 and YopE
O3 against ubiquitination
may aid yersiniae of these serotypes to intensify their immunomodulatory
activities.

DISCUSSION
This study demonstrates that YopE isotypes from diverse pathogenic
Y. enterocolitica serogroups differ in their dispositions to
become ubiquitinated and degraded by the host cell proteasome.
The susceptibility to ubiquitination and degradation concomitantly
determines the effect of YopE on the host cell. YopE of
Y. enterocolitica serotypes O3 and O9 resisted ubiquitination and exerted an enhanced
cytotoxic effect on infected host cells, whereas cytotoxicity
conferred by serogroup O8 YopE was substantially less pronounced.
The reduced activity of YopE
O8 resulted from polyubiquitination
and efficient degradation of YopE
O8 through the proteasome pathway.
To relate the effects of the different YopE isotypes to single
amino acids, we compared the amino acid sequences of YopE
O8,
YopE
O9, and YopE
O3. We identified two lysine residues (K62 and
K75) as polyubiquitin acceptor sites of YopE
O8 that are absent
in YopE
O9 and YopE
O3. Exchange of the lysine residues of YopE
O8 for arginine and glutamine of YopE
O9 and vice versa revealed
that either lysine can be modified by polyubiquitination and
mediate YopE degradation. These data show that functional differences
exist between genetically highly homologous members of YopE
proteins from diverse
Y. enterocolitica serotypes. These differences
are due to distinct stabilities of the respective YopE isotypes
inside the host cell. Interestingly, a search in the published
protein sequence databases showed that lysine-62 and lysine-75
are unique to YopE from
Y. enterocolitica serogroup O8 and are
not found in any other YopE proteins such as those from
Y. pestis or
Y. pseudotuberculosis. This indicates that ubiquitination
and destabilization of YopE by the host cell proteasome is a
specific feature of
Y. enterocolitica serogroup O8.
The species Y. enterocolitica comprises a biochemically, serologically, and genetically heterogenous group of organisms. While the serotypes O3 and O9 are most frequently isolated in Europe and Japan, serotype O8 causes infections predominantly in North America. This reflects the independent evolution of the different Y. enterocolitica lineages (19, 47). Y. pestis and Y. pseudotuberculosis are, in contrast, closely related. They display gene homology of nearly 97%, and it was proposed that Y. pestis separated from Y. pseudotuberculosis just 1,500 to 20,000 years ago (1, 47). However, the three pathogenic Yersinia spp. share a related virulence plasmid, termed pYV, which encodes the Yersinia Yop virulon including YopE. It is believed that the pYV plasmids of the diverse Yersinia spp. arose from a common predecessor plasmid that was brought in an environmental, nonpathogenic Yersinia strain to form the ancestor of pathogenic yersiniae (47). Comparison of the virulence plasmids of Y. enterocolitica serogroups O8 and O9 and of Y. pestis reveals deletions, insertions, and rearrangements of DNA sequences (37). This indicates that the virulence plasmids have evolved separately along with the genomes after divergence of the different clades (19, 37, 47). DNA cross-hybridization experiments have shown that the virulence plasmids of the Y. enterocolitica serogroups O3 and O9 display 90% nucleotide identity with one another but only 75% identity with the plasmid from serogroup O8 (16, 37). Y. enterocolitica serotype O8, furthermore, shares only 55% nucleotide identity with the virulence plasmids from Y. pestis and Y. pseudotuberculosis (30, 37). These observations support the concept that Y. enterocolitica serotype O8 arose by a specific evolutionary path, distant from serogroups O3 and O9 (37, 47). This evolutionary aspect can explain the genetic background that determines the specificity in the stability and function of YopEO8.
The order of evolution of the two lysines in YopEO8 and their significance for Yersinia virulence are, however, still unclear. Our results show that the absence of the two lysines increases the stability and the activity of YopE inside the host cell. It is tempting to speculate that the lysines were lost in the majority of the Yersinia lineages during evolution to enhance their virulence. On the other hand, because only YopEO8 carries lysine-62 and -75, it appears more reasonable to assume that these lysines specifically evolved in Y. enterocolitica serogroup O8 from a predecessor strain originally lacking these residues. The lysines may now fulfill a specific function in the pathogenesis of Y. enterocolitica serogroup O8 infection. The formation of the lysines and the concomitant destabilization of YopEO8 may help to mitigate the virulence of Y. enterocolitica O8. In fact, this could be advantageous for Y. enterocolitica O8 infection. Serotype O8 Y. enterocolitica possesses a number of virulence factors that are absent in the other Y. enterocolitica serogroups. These include the yersiniabactin siderophore system, which is encoded by the high-pathogenicity island (7, 34), the chromosomally encoded type III protein secretion system Ysa (11, 14, 43), and the type II secretion system Yts1 (20). Furthermore, a number of virulence proteins encoded by the pYV plasmid from Y. enterocolitica serogroup O8 are more active than the respective proteins from the other Yersinia clades, i.e., YopP/YopJ and LcrV (10, 33, 36, 48). Y. enterocolitica O8 is consequently characterized by enhanced pathogenicity in the mouse infection model. Y. enterocolitica O8 may therefore have established strategies to counteract excessive bacterial virulence in order to prevent premature consumption of the infected host. The ubiquitination and concomitant reduction of the half-life of YopE could be a mechanism that dampens Y. enterocolitica O8 virulence. This may then enable prolonged, productive bacterial infection. Alternatively, since YopE also possesses a regulatory role in the translocation of the Yops by destabilizing the translocation channel (44), excessive activity of YopEO8 could be counterproductive for efficient Yop translocation. The specific regulation of the stability of YopEO8 by the host cell proteasome may consequently help Y. enterocolitica serogroup O8 to fine-tune its immunomodulatory effects on the host cell. Thus, by balancing the activity of YopEO8, the proteasome could affect the course of Y. enterocolitica serotype O8 infection in the compromised host. It has been shown that YopEO8 supports the colonization of liver and spleen with yersiniae in infected mice (42). The activity of the proteasome could therefore influence the bacterial counts in the peripheral lymphoid tissue along with the YopE levels. The quantitative effect of YopEO8 ubiquitination and inactivation on the dissemination of the bacteria in the host will be specified in detail in future studies.

ACKNOWLEDGMENTS
This work was supported by grants from the Deutsche Forschungsgemeinschaft
(grants DFG Ru788/1 and -2).
We are grateful to Nicole Czymmeck for expert technical assistance. We thank Gudrun Pfaffinger for support in establishing the immunoprecipitation assays. We also thank G. R. Cornelis and Mathias Treier for providing us with the E40 Yersinia strain and the ubiquitin expression vector, respectively.

FOOTNOTES
* Corresponding author. Mailing address: Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. Phone: 49 40 42803 7035. Fax: 49 40 42803 3250. E-mail:
k.ruckdeschel{at}uke.uni-hamburg.de 
Published ahead of print on 2 July 2007. 
Editor: J. B. Bliska

REFERENCES
1 - Achtman, M., K. Zurth, G. Morelli, G. Torrea, A. Guiyoule, and E. Carniel. 1999. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl. Acad. Sci. USA 96:14043-14048.[Abstract/Free Full Text]
2 - Aepfelbacher, M., and J. Heesemann. 2001. Modulation of Rho GTPases and the actin cytoskeleton by Yersinia outer proteins (Yops). Int. J. Med. Microbiol. 291:269-276.[CrossRef][Medline]
3 - Balachandran, P., L. Dragone, L. Garrity-Ryan, A. Lemus, A. Weiss, and J. Engel. 2007. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J. Clin. Investig. 117:419-427.[CrossRef][Medline]
4 - Black, D. S., and J. B. Bliska. 1997. Identification of p130Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J. 16:2730-2744.[CrossRef][Medline]
5 - Black, D. S., and J. B. Bliska. 2000. The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence. Mol. Microbiol. 37:515-527.[CrossRef][Medline]
6 - Bliska, J. B. 2000. Yop effectors of Yersinia spp. and actin rearrangements. Trends Microbiol. 8:205-208.[CrossRef][Medline]
7 - Carniel, E. 2001. The Yersinia high-pathogenicity island: an iron-uptake island. Microbes Infect. 3:561-569.[CrossRef][Medline]
8 - Carter, P. B., C. F. Varga, and E. E. Keet. 1973. New strain of Yersinia enterocolitica pathogenic for rodents. Appl. Microbiol. 26:1016-1018.[Medline]
9 - Cornelis, G. R. 2002. The Yersinia Ysc-Yop "type III" weaponry. Nat. Rev. Mol. Cell. Biol. 3:742-752.[CrossRef][Medline]
10 - Denecker, G., S. Totemeyer, L. J. Mota, P. Troisfontaines, I. Lambermont, C. Youta, I. Stainier, M. Ackermann, and G. R. Cornelis. 2002. Effect of low- and high-virulence Yersinia enterocolitica strains on the inflammatory response of human umbilical vein endothelial cells. Infect. Immun. 70:3510-3520.[Abstract/Free Full Text]
11 - Foultier, B., P. Troisfontaines, S. Muller, F. R. Opperdoes, and G. R. Cornelis. 2002. Characterization of the ysa pathogenicity locus in the chromosome of Yersinia enterocolitica and phylogeny analysis of type III secretion systems. J. Mol. Evol. 55:37-51.[CrossRef][Medline]
12 - Glickman, M. H., and A. Ciechanover. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82:373-428.[Abstract/Free Full Text]
13 - Haase, R., C. J. Kirschning, A. Sing, P. Schröttner, K. Fukase, S. Kusumoto, H. Wagner, J. Heesemann, and K. Ruckdeschel. 2003. A dominant role of Toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J. Immunol. 171:4294-4303.[Abstract/Free Full Text]
14 - Haller, J. C., S. Carlson, K. J. Pederson, and D. E. Pierson. 2000. A chromosomally encoded type III secretion pathway in Yersinia enterocolitica is important in virulence. Mol. Microbiol. 36:1436-1446.[CrossRef][Medline]
15 - Heesemann, J., U. Gross, N. Schmidt, and R. Laufs. 1986. Immunochemical analysis of plasmid-encoded proteins released by enteropathogenic Yersinia sp. grown in calcium-deficient media. Infect. Immun. 54:561-567.[Abstract/Free Full Text]
16 - Heesemann, J., C. Keller, R. Morawa, N. Schmidt, H. J. Siemens, and R. Laufs. 1983. Plasmids of human strains of Yersinia enterocolitica: molecular relatedness and possible importance for pathogenesis. J. Infect. Dis. 147:107-115.[Medline]
17 - Heesemann, J., and R. Laufs. 1983. Construction of a mobilizable Yersinia enterocolitica virulence plasmid. J. Bacteriol. 155:761-767.[Abstract/Free Full Text]
18 - Heesemann, J., A. Sing, and K. Trülzsch. 2006. Yersinia's stratagem: targeting innate and adaptive immune defense. Curr. Opin. Microbiol. 9:55-61.[CrossRef][Medline]
19 - Howard, S. L., M. W. Gaunt, J. Hinds, A. A. Witney, R. Stabler, and B. W. Wren. 2006. Application of comparative phylogenomics to study the evolution of Yersinia enterocolitica and to identify genetic differences relating to pathogenicity. J. Bacteriol. 188:3645-3653.[Abstract/Free Full Text]
20 - Iwobi, A., J. Heesemann, E. Garcia, E. Igwe, C. Noelting, and A. Rakin. 2003. Novel virulence-associated type II secretion system unique to high-pathogenicity Yersinia enterocolitica. Infect. Immun. 71:1872-1879.[Abstract/Free Full Text]
21 - Kloetzel, P. M., and F. Ossendorp. 2004. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16:76-81.[CrossRef][Medline]
22 - Kubori, T., and J. E. Galan. 2003. Temporal regulation of Salmonella virulence effector function by proteasome-dependent protein degradation. Cell 115:333-342.[CrossRef][Medline]
23 - Lee, D. H., and A. L. Goldberg. 1998. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell. Biol. 8:397-403.[CrossRef][Medline]
24 - Meng, L., R. Mohan, B. H. Kwok, M. Elofsson, N. Sin, and C. M. Crews. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. USA 96:10403-10408.[Abstract/Free Full Text]
25 - Mittal, R., S. Y. Peak-Chew, and H. T. McMahon. 2006. Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc. Natl. Acad. Sci. USA 103:18574-18579.[Abstract/Free Full Text]
26 - Mukherjee, S., G. Keitany, Y. Li, Y. Wang, H. L. Ball, E. J. Goldsmith, and K. Orth. 2006. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312:1211-1214.[Abstract/Free Full Text]
27 - Orth, K. 2002. Function of the Yersinia effector YopJ. Curr. Opin. Microbiol. 5:38-43.[CrossRef]
28 - Persson, C., N. Carballeira, H. Wolf-Watz, and M. Fällman. 1997. The PTPase YopH inhibits uptake of Yersinia, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J. 16:2307-2318.[CrossRef][Medline]
29 - Pickart, C. M., and R. E. Cohen. 2004. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell. Biol. 5:177-187.[CrossRef][Medline]
30 - Portnoy, D. A., H. Wolf-Watz, I. Bolin, A. B. Beeder, and S. Falkow. 1984. Characterization of common virulence plasmids in Yersinia species and their role in the expression of outer membrane proteins. Infect. Immun. 43:108-114.[Abstract/Free Full Text]
31 - Prehna, G., M. I. Ivanov, J. B. Bliska, and C. E. Stebbins. 2006. Yersinia virulence depends on mimicry of host Rho-family nucleotide dissociation inhibitors. Cell 126:869-880.[CrossRef][Medline]
32 - Ruckdeschel, K., G. Pfaffinger, K. Trülzsch, G. Zenner, K. Richter, J. Heesemann, and M. Aepfelbacher. 2006. The proteasome pathway destabilizes Yersinia outer protein E and represses its antihost cell activities. J. Immunol. 176:6093-6102.[Abstract/Free Full Text]
33 - Ruckdeschel, K., K. Richter, O. Mannel, and J. Heesemann. 2001. Arginine-143 of Yersinia enterocolitica YopP crucially determines isotype-related NF-
B suppression and apoptosis induction in macrophages. Infect. Immun. 69:7652-7662.[Abstract/Free Full Text] 34 - Schubert, S., A. Rakin, and J. Heesemann. 2004. The Yersinia high-pathogenicity island (HPI): evolutionary and functional aspects. Int. J. Med. Microbiol. 294:83-94.[CrossRef][Medline]
35 - Shao, F., P. M. Merritt, Z. Bao, R. W. Innes, and J. E. Dixon. 2002. A Yersinia effector and a Pseudomonas avirulence protein define a family of cysteine proteases functioning in bacterial pathogenesis. Cell 109:575-588.[CrossRef][Medline]
36 - Sing, A., D. Reithmeier-Rost, K. Granfors, J. Hill, A. Roggenkamp, and J. Heesemann. 2005. A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence. Proc. Natl. Acad. Sci. USA 102:16049-16054.[Abstract/Free Full Text]
37 - Snellings, N. J., M. Popek, and L. E. Lindler. 2001. Complete DNA sequence of Yersinia enterocolitica serotype O:8 low-calcium-response plasmid reveals a new virulence plasmid-associated replicon. Infect. Immun. 69:4627-4638.[Abstract/Free Full Text]
38 - Sory, M. P., A. Boland, I. Lambermont, and G. R. Cornelis. 1995. Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Proc. Natl. Acad. Sci. USA 92:11998-12002.[Abstract/Free Full Text]
39 - Thrower, J. S., L. Hoffman, M. Rechsteiner, and C. M. Pickart. 2000. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19:94-102.[CrossRef][Medline]
40 - Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787-798.[CrossRef][Medline]
41 - Trülzsch, K., A. Roggenkamp, M. Aepfelbacher, G. Wilharm, K. Ruckdeschel, and J. Heesemann. 2003. Analysis of chaperone-dependent Yop secretion/translocation and effector function using a mini-virulence plasmid of Yersinia enterocolitica. Int. J. Med. Microbiol. 293:167-177.[CrossRef][Medline]
42 - Trülzsch, K., T. Sporleder, E. I. Igwe, H. Rüssmann, and J. Heesemann. 2004. Contribution of the major secreted Yops of Yersinia enterocolitica O:8 to pathogenicity in the mouse infection model. Infect. Immun. 72:5227-5234.[Abstract/Free Full Text]
43 - Venecia, K., and G. M. Young. 2005. Environmental regulation and virulence attributes of the Ysa type III secretion system of Yersinia enterocolitica biovar 1B. Infect. Immun. 73:5961-5977.[Abstract/Free Full Text]
44 - Viboud, G. I., and J. B. Bliska. 2001. A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes. EMBO J. 20:5373-5382.[CrossRef][Medline]
45 - Von Pawel-Rammingen, U., M. V. Telepnev, G. Schmidt, K. Aktories, H. Wolf-Watz, and R. Rosqvist. 2000. GAP activity of the Yersinia YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. Mol. Microbiol. 36:737-748.[CrossRef][Medline]
46 - Wilharm, G., V. Lehmann, K. Krauss, B. Lehnert, S. Richter, K. Ruckdeschel, J. Heesemann, and K. Trülzsch. 2004. Yersinia enterocolitica type III secretion depends on the proton motive force but not on the flagellar motor components MotA and MotB. Infect. Immun. 72:4004-4009.[Abstract/Free Full Text]
47 - Wren, B. W. 2003. The yersiniae—a model genus to study the rapid evolution of bacterial pathogens. Nat. Rev. Microbiol. 1:55-64.[CrossRef][Medline]
48 - Zauberman, A., S. Cohen, E. Mamroud, Y. Flashner, A. Tidhar, R. Ber, E. Elhanany, A. Shafferman, and B. Velan. 2006. Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis. Infect. Immun. 74:3239-3250.[Abstract/Free Full Text]
49 - Zhang, Y., W. Higashide, S. Dai, D. M. Sherman, and D. Zhou. 2005. Recognition and ubiquitination of Salmonella type III effector SopA by a ubiquitin E3 ligase, HsRMA1. J. Biol. Chem. 280:38682-38688.[Abstract/Free Full Text]
Infection and Immunity, September 2007, p. 4423-4431, Vol. 75, No. 9
0019-9567/07/$08.00+0 doi:10.1128/IAI.00528-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Roppenser, B., Roder, A., Hentschke, M., Ruckdeschel, K., Aepfelbacher, M.
(2009). Yersinia enterocolitica differentially modulates RhoG activity in host cells. J. Cell Sci.
122: 696-705
[Abstract]
[Full Text]